Genomic and immune determinants of response to CD3 x CD20 bispecific antibodies in aggressive B-cell lymphoma
Sign Up to like & getrecommendations! Published in 2025 at "Blood"
DOI: 10.1182/blood-2025-3542
Abstract: CD3 x CD20 bispecific antibodies (BsAb)have been approved for use in relapsed/refractory (R/R) diffuse large B-cell lymphomas (DLBCLs) based on its deep and durable response and manageable toxicity profiles. While emerging data suggest that tumor… read more here.
Keywords: gcb hot; cd3 cd20; response; cell ... See more keywords
Epcoritamab (GEN3013; DuoBody-CD3×CD20) to induce complete response in patients with relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL): Complete dose escalation data and efficacy results from a phase I/II trial.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.38.15_suppl.8009
Abstract: 8009Background: CD3×CD20 bispecific antibodies (bsAbs) have demonstrated promising results for the treatment of pts with R/R B-NHL. Epcoritamab is a novel subcutaneously administered bsAb with a fa... read more here.
Keywords: epcoritamab gen3013; duobody cd3; cd3 cd20; cd20 ... See more keywords